Table 5.
Proportion of patients in the “good”, “moderate”, and “poor” functioning clusters at last observation, by baseline functional cluster and treatment group
| Treatment/functioning cluster at baseline | Functioning cluster at endpoint
|
Total, n | ||
|---|---|---|---|---|
| “Good” | “Moderate” | “Poor” | ||
| Olanzapine-LAI, n (%) | ||||
| “Good” | 35 (76.1) | 11 (23.9) | 0 (0.0) | 46 |
| “Moderate” | 26 (18.8) | 93 (67.4) | 19 (13.8) | 138 |
| “Poor” | 5 (9.1) | 20 (36.4) | 30 (54.5) | 55 |
| Total, n (%) | 66 (27.6) | 124 (51.9) | 49 (20.5) | 239 |
| Oral olanzapine, n (%) | ||||
| “Good” | 25 (73.5) | 8 (23.5) | 1 (2.9) | 34 |
| “Moderate” | 30 (19.6) | 110 (71.9) | 13 (8.5) | 153 |
| “Poor” | 1 (2.4) | 18 (42.9) | 23 (54.8) | 42 |
| Total, n (%) | 56 (24.5) | 136 (59.4) | 37 (16.2) | 229 |
Note:
There were no statistical differences between the change from baseline to endpoint for each of the functioning clusters when comparing olanzapine-LAI and oral olanzapine. Percentages may not =100, due to rounding.
Abbreviation: LAI, long-acting injection.